Search results for: Pricing and Reimbursement
Filter search results
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
…and reimbursement policies in Germany: current and future trends; Pricing and reimbursement policies in UK: a current and future trends; Pricing and reimbursement policies in Italy: current and future trends;…
Evidence on Valued Based Pricing and Reimbursement Schemes
30 September 2011
…and performance-based reimbursement. Dr. Mestre-Ferrandiz Despite the potential importance of value-based schemes for influencing the pricing, reimbursement and use of pharmaceuticals, the literature contains remarkably little hard evidence about their…
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
…practices should be shared and that, to seize opportunities, companies should monitor and respond to public sentiment, proactively address any negative issues, and invest in R&D and technology to deal…
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
…sustainable, and the innovation pipeline is robust. In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…introducing effective HTA and related priority setting mechanisms in order to support both the introduction of universal health care and more efficient pricing and reimbursement mechanisms based on value-based pricing….
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…be low. Benefits and weaknesses of TEVs and of the European Commission’s proposals The TEV proposal has been controversial and we set out the arguments for and against drawing on…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…In reality, indication launches within a country can be costly, with significant investment needed in regulatory and HTA submission and compliance, manufacturing and distribution adjustments, marketing and commercialisation, and any…
Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
15 December 2011
…Pricing and Reimbursement The OHE team addressed various aspects of pricing and reimbursement (P&R) during the last quarter of 2011. At the ISPOR Europe meeting in November, Adrian Towse and…